SCHEMBL23628748

SCHEMBL23628748

FC(F)(F)c1ccc(N2C[C@@H](CN3CCC4(CCNC4)C3)[C@H](C(F)(F)F)C2)c2nccnc12

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 5/20 0.37
CYP3A4 P08684 5/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
TSHR P16473 3/20 0.35
ALDH1A1 P00352 3/20 0.33
MAPK1 P28482 1/20 0.33
PDCD1LG2 Q9BQ51 1/20 0.33
CD274 Q9NZQ7 1/20 0.33
HSD17B10 Q99714 2/20 0.32
NCF1 P14598 1/20 0.32
HPGD P15428 1/20 0.32
CYP1A2 P05177 1/20 0.32
NPY2R P49146 1/20 0.32
KHK P50053 2/20 0.32
ROCK1 Q13464 1/20 0.32
CDC42BPB Q9Y5S2 1/20 0.32
MCHR1 Q99705 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23628750 1.00 CYP2D6 (0.37) CYP2D6CYP3A4CYP2C9CYP2C19TSHR
SCHEMBL23628744 1.00 CYP2D6 (0.37) CYP2D6CYP3A4CYP2C9CYP2C19TSHR
SCHEMBL23760663 0.87 TLR8 (0.37) CYP2D6CYP3A4CYP2C9CYP2C19TSHR
SCHEMBL23628828 0.87 TLR8 (0.37) CYP2D6CYP3A4CYP2C9CYP2C19TSHR
SCHEMBL23628767 0.82 CYP2D6 (0.38) CYP2D6CYP3A4CYP2C9CYP2C19TSHR
SCHEMBL23628763 0.82 CYP2D6 (0.38) CYP2D6CYP3A4CYP2C9CYP2C19TSHR
SCHEMBL23628766 0.82 CYP2D6 (0.38) CYP2D6CYP3A4CYP2C9CYP2C19TSHR
SCHEMBL23760700 0.82 CYP2D6 (0.38) CYP2D6CYP3A4CYP2C9CYP2C19TSHR
SCHEMBL23628870 0.82 TLR8 (0.36) CYP2D6CYP3A4CYP2C9CYP2C19TSHR
SCHEMBL23760718 0.82 TLR8 (0.38) CYP3A4CYP1A2ROCK1CDC42BPB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210253575-A1 PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN-LA ROCHE INC. (US) 2021-08-19 US claimed
EP-3847165-A1 NOVEL PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2021-07-14 EP claimed
US-20210253575-A1 PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN-LA ROCHE INC. (US) 2021-08-19 US disclosed
EP-3847165-A1 NOVEL PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2021-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210253575-A1 PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE ARG1, PRMT1, PADI1 CYP2D6 2859/4885CYP3A4 3575/4885CYP2C9 3157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.